Effects of Coffee on Hepatic Steatosis Induced by a High Fructose Diet

NCT ID: NCT00827450

Last Updated: 2012-02-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess

* whether coffee consumption protects against fructose-induced hepatic steatosis in healthy humans
* whether the protective effect of coffee is dependent on it's antioxidant composition

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epidemiological studies suggest that coffee consumption improves glucose homeostasis in insulin resistant subjects. An increase in intrahepatic lipids (hepatic steatosis) is highly prevalent in patients with the metabolic syndrome and may be used as a marker of altered hepatic lipid metabolism. Such an increased hepatic lipids content can be experimentally produced in healthy humans by a 6-day high fructose diet.

The purpose of this study is to evaluate whether coffee prevents hepatic lipid deposition in healthy male subjects fed a fructose-rich hypercaloric diet. Both caffeine and antioxidants (yet unspecified) may be involved.. To sort out the role of caffeine and antioxidants, we will test 3 different soluble coffee, ie fully torrefied decaffeinated coffee , partially torrefied decaffeinated coffee, and partially torrefied caffeinated coffee.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Steatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ctl

control isocaloric diet; no coffee

Group Type PLACEBO_COMPARATOR

Ctl

Intervention Type DIETARY_SUPPLEMENT

Control, isocaloric diet; no coffee

HF

Hypercaloric. high fructose diet; no coffee

Group Type PLACEBO_COMPARATOR

High fructose diet; no coffee

Intervention Type DIETARY_SUPPLEMENT

Hypercaloric, high fructose diet; no coffee

C1

Hypercaloric, high fructose diet; caffeine-free, torrefied coffee

Group Type EXPERIMENTAL

fully torrefied, caffeine-free coffee

Intervention Type DIETARY_SUPPLEMENT

Hypercaloric, high fructose diet + coffee

C2

Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee

Group Type EXPERIMENTAL

partially torrefied, caffeine-free coffee

Intervention Type DIETARY_SUPPLEMENT

Hypercaloric, high fructose diet + coffee

C3

Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee

Group Type EXPERIMENTAL

Partially torrefied, caffeinated coffee

Intervention Type DIETARY_SUPPLEMENT

Hypercaloric, high fructose diet + coffee

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ctl

Control, isocaloric diet; no coffee

Intervention Type DIETARY_SUPPLEMENT

High fructose diet; no coffee

Hypercaloric, high fructose diet; no coffee

Intervention Type DIETARY_SUPPLEMENT

fully torrefied, caffeine-free coffee

Hypercaloric, high fructose diet + coffee

Intervention Type DIETARY_SUPPLEMENT

partially torrefied, caffeine-free coffee

Hypercaloric, high fructose diet + coffee

Intervention Type DIETARY_SUPPLEMENT

Partially torrefied, caffeinated coffee

Hypercaloric, high fructose diet + coffee

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between 19 and 15 kg/m2
* less than 30 min physical activity /day
* habitual coffee consumption less than three cupy /day
* consumption of caffeine-containing sodas less than 2 servings/day
* non-smoker

Exclusion Criteria

* consumption of alcohol more than 40g/day
* presence of metallic foreign bodies
* history of eye surgery
* family history of diabetes mellitus
* history of food intolerance
* vegetarians
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nestlé Research Center, Vers-chez-les-blanc, Switzerland

UNKNOWN

Sponsor Role collaborator

University of Lausanne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Luc Tappy, MD

professor of physiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luc Tappy, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Physiology, University of Lausanne, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre d'investigations cliniques "cardiomet"/ CHUV

Lausanne, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Lecoultre V, Carrel G, Egli L, Binnert C, Boss A, MacMillan EL, Kreis R, Boesch C, Darimont C, Tappy L. Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men. Am J Clin Nutr. 2014 Feb;99(2):268-75. doi: 10.3945/ajcn.113.069526. Epub 2013 Nov 20.

Reference Type DERIVED
PMID: 24257718 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COLIBRI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Quantifying Steatosis in Liver Transplant Donors
NCT02579408 ACTIVE_NOT_RECRUITING